Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 64

1.

Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents.

Collinson FJ, Seligmann J, Perren TJ.

Curr Oncol Rep. 2012 Dec;14(6):509-18. doi: 10.1007/s11912-012-0274-4. Review.

PMID:
22948277
[PubMed - indexed for MEDLINE]
2.

A phase 3 trial of bevacizumab in ovarian cancer.

Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators.

N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. Erratum in: N Engl J Med. 2012 Jan 19;366(3):284.

PMID:
22204725
[PubMed - indexed for MEDLINE]
Free Article
3.

Mucinous tumours of the ovary.

Naik JD, Seligmann J, Perren TJ.

J Clin Pathol. 2012 Jul;65(7):580-4. doi: 10.1136/jclinpath-2011-200320. Epub 2011 Oct 19. Review.

PMID:
22011449
[PubMed - indexed for MEDLINE]
4.

Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.

Miles D, Roché H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A, Murray JL, Ibrahim NK; Theratope® Study Group.

Oncologist. 2011;16(8):1092-100. doi: 10.1634/theoncologist.2010-0307. Epub 2011 May 14.

PMID:
21572124
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Anthracycline-induced cardiomyopathy in siblings with early breast cancer.

Young AC, Mercer B, Perren TJ, Dodwell D.

Ann Oncol. 2011 Jul;22(7):1692. doi: 10.1093/annonc/mdr272. Epub 2011 May 9. No abstract available.

PMID:
21555361
[PubMed - indexed for MEDLINE]
Free Article
6.

The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma.

Vasudev NS, Trigonis I, Cairns DA, Hall GD, Jackson DP, Broadhead T, Buxton J, Hutson R, Nugent D, Perren TJ.

Arch Gynecol Obstet. 2011 Jul;284(1):221-7. doi: 10.1007/s00404-010-1655-2. Epub 2010 Aug 29.

PMID:
20803207
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Recent EORTC and MRC UK studies: implications for imaging ovarian cancer.

Spencer JA, Perren TJ.

Cancer Imaging. 2010 Jul 6;10:135-6. doi: 10.1102/1470-7330.2010.0018. Review.

PMID:
20605760
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series.

Agarwal R, Gourley C, Perren TJ, Reed N, Parkin DE, Carty K, Rustin GJ, Gabra H, Paul J, Gore ME, Kaye SB; Scottish Gynecological Cancers Trials Group.

Eur J Cancer. 2010 Jul;46(11):2020-6. doi: 10.1016/j.ejca.2010.03.006. Epub 2010 Apr 13.

PMID:
20395128
[PubMed - indexed for MEDLINE]
9.

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

Del Campo JM, Roszak A, Bidzinski M, Ciuleanu TE, Hogberg T, Wojtukiewicz MZ, Poveda A, Boman K, Westermann AM, Lebedinsky C; Yondelis Ovarian Cancer Group.

Ann Oncol. 2009 Nov;20(11):1794-802. doi: 10.1093/annonc/mdp198. Epub 2009 Jun 25.

PMID:
19556318
[PubMed - indexed for MEDLINE]
Free Article
10.

Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.

Waters SH, Gillibrand A, Berry H, Kumar S, Velikova G, Dodwell DJ, Perren TJ.

Cancer Chemother Pharmacol. 2009 Jul;64(2):407-12. doi: 10.1007/s00280-009-1021-x. Epub 2009 May 20.

PMID:
19455333
[PubMed - indexed for MEDLINE]
11.

Development of antiangiogenic agents for ovarian cancer.

Collinson FJ, Hall GD, Perren TJ, Jayson GC.

Expert Rev Anticancer Ther. 2008 Jan;8(1):21-32. Review.

PMID:
18095880
[PubMed - indexed for MEDLINE]
12.

Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.

Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, Tonge RP, Hartley JL, Nickson JA, Rayner SJ, Johnston C, Dieplinger B, Hubalek M, Wilkinson N, Perren TJ, Kehoe S, Hall GD, Daxenbichler G, Dieplinger H, Selby PJ, Banks RE.

Clin Cancer Res. 2007 Dec 15;13(24):7370-9.

PMID:
18094419
[PubMed - indexed for MEDLINE]
Free Article
13.

Timing of breast cancer surgery in relation to menstrual cycle phase: no effect on 3-year prognosis: the ITS Study.

Thorpe H, Brown SR, Sainsbury JR, Perren TJ, Hiley V, Dowsett M, Nejim A, Brown JM.

Br J Cancer. 2008 Jan 15;98(1):39-44. Epub 2007 Dec 18.

PMID:
18087287
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Women with peritoneal carcinomatosis of unknown origin: Efficacy of image-guided biopsy to determine site-specific diagnosis.

Hewitt MJ, Anderson K, Hall GD, Weston M, Hutson R, Wilkinson N, Perren TJ, Lane G, Spencer JA.

BJOG. 2007 Jan;114(1):46-50.

PMID:
17233859
[PubMed - indexed for MEDLINE]
15.

Image-guided biopsy in women with breast cancer presenting with peritoneal carcinomatosis.

Hewitt MJ, Hall GD, Wilkinson N, Perren TJ, Lane G, Spencer JA.

Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:108-10.

PMID:
16515576
[PubMed - indexed for MEDLINE]
16.

Routine chest radiography following imaging-guided placement of tunneled central lines: a waste of time, money, and radiation.

Kessel DO, Taylor EJ, Robertson I, Patel JV, Denton LJ, Perren TJ.

Nutr Clin Pract. 2002 Apr;17(2):105-9.

PMID:
16214971
[PubMed]
17.

Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.

Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S, Friedrichs K, Pinter T, Van Belle S, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Perren TJ, Leroy JY, Rouas G, Sotiriou C, Piccart M, Larsimont D.

Mol Cancer Ther. 2004 Oct;3(10):1207-14.

PMID:
15486187
[PubMed - indexed for MEDLINE]
Free Article
18.

Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study.

Hall GD, Brown JM, Coleman RE, Stead M, Metcalf KS, Peel KR, Poole C, Crawford M, Hancock B, Selby PJ, Perren TJ.

Br J Cancer. 2004 Aug 16;91(4):621-6.

PMID:
15305182
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study.

Humphreys AC, Dent J, Rodwell S, Crawford SM, Joffe JK, Bradley C, Dodwell D, Perren TJ.

Br J Cancer. 2004 Jun 1;90(11):2131-4.

PMID:
15150554
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial.

Smith IE, A'Hern RP, Coombes GA, Howell A, Ebbs SR, Hickish TF, O'Brien ME, Mansi JL, Wilson CB, Robinson AC, Murray PA, Price CG, Perren TJ, Laing RW, Bliss JM; TOPIC Trial Group.

Ann Oncol. 2004 May;15(5):751-8.

PMID:
15111342
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk